Veltuzumab
Jump to navigation
Jump to search
Template:Short description Template:Drugbox Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.[1][2] since December 2011[update]Template:Dated maintenance category (articles)Script error: No such module "Check for unknown parameters"., it is undergoing Phase I/II clinical trials.[3] When used with milatuzumab it showed activity.[4]
This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.[5]
In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).[6] A phase II trial is planned to run for 5 years.[6]
See also
References
<templatestyles src="Reflist/styles.css" />
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
- ↑ Script error: No such module "Citation/CS1".
- ↑ Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ a b Script error: No such module "citation/CS1".
Script error: No such module "Check for unknown parameters".